NCT07543250 2026-04-21A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast CancerPeking University Cancer Hospital & InstituteNot yet recruiting100 enrolled